TBIO - הכנסה תפעולית לפני ניכוי פחת Telesis Bio

Telesis Bio, Inc. (TBIO) is developing an IT ecosystem for gene printing by locking laboratories into proprietary consumables. This eco-friendly approach reduces the carbon footprint by localizing DNA synthesis. Revenue is based on the sale of BioXp systems. EBITDA analytics demonstrate cash generation dynamics, where the level captures the current state of operating profit, helping to avoid purchasing the asset at historical peaks.

Absolute operating profit captures the daily liquidity inflow from core operations, allowing investors to differentiate actual cash flow from accounting accruals and identify value trap risks. By analyzing the absolute EBITDA volume, one can assess the monetization efficiency of Telesis Bio (TBIO) DNA synthesizers, whose implementation in scientific research reduces the carbon footprint by optimizing reagent logistics.